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a b s t r a c t
Purpose: To evaluate dosimetric and clinical findings of MRI-guided HDR brachytherapy (HDR-
B) for cervical carcinoma.
Material and methods: All patients had a CT, MRI and pelvic-paraaortic lymphadenectomy.
Treatment: pelvic (+/−)para-aortic3D/IMRT radiotherapy (45 Gy), weekly cisplatin and HDR-
B and pelvic node/parametrial boost 60 Gy until interstitial brachytherapy was done. Two
implants: 2008–2011: 5 fractions of 6 Gy, 2011: 2016, 4 fractions of 7 Gy. MRI/TAC were done
in each implant. The following were defined: GTV, CTH-HR, CTV-IR; OAR: rectum, bladder
and sigmoid.
Results: From 2007 to 2016: 57 patients. Patients: T1b2-T2a: 4p, T2b 41p, T3a: 2p; T3B 8p
T4a: 2p; N0: 32p, N1 21p, no lymphadenectomy: 4p. Median follow up: 74.6 m (16–122 m),
recurrence: 5p local, 6p node, 9p metastasis and 37p without recurrence.
Local control 5 years: 90.1%; Ib2-IIB: 94.8%, III-IVa: 72.2%. (p:0.01). RDFS 5y was 92.5%; IB2-
IIB: 93%, III: 85% (p:0.024); for pN0: 100%; pN+ iliac-paraaortic: 71.4% (p: 0.007). MFS 5y was
84.1%. Overall survival (OS) at 5y: 66.6% and the cancer specific survival (CEOS) was 74%.
Univariate analysis survival: stage Ib2-II 83% vs. III-IVa 41% (p = 0.001); histology: squamous
78%, adenocarcinoma 59.7% (p: ns); lymph node: N0 85% vs. PA+P− 72%, and PA+P+ 35%
(p = 0.010). In relation with: HR-CTV dose > 85 Gy, CEOS: 82.5% vs. 77%, and volume CTV-
HR < 30 cc: 81.8% and >30 cc: 67%; p: ns. Acute grade 2–3 toxicity: rectal 15.7%, intestinal
15.7% and vesical 15.5%.
Conclusion: Use of interstitial HDR-BQ guided by RM increased CTV-HR dose and local control,
like EMBRACE results. Nodal boost improves RDFS and perhaps OS.
Published by Elsevier Sp. z o.o. on behalf of Greater Poland Cancer Centre.
∗ Corresponding author.
E-mail address: evillafi@navarra.es (E. Villafranca).
https://doi.org/10.1016/j.rpor.2018.09.006
1507-1367/Published by Elsevier Sp. z o.o. on behalf of Greater Poland Cancer Centre.
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1. Background
Cervical cancer is the second most frequent gynaecologi-
cal tumour worldwide. Its development is closely related
to human papilloma virus infection. Surgical treatment is
reserved for early tumour stages IA, IBA and IIA1. Treatment
is based on the combination of external beam radiotherapy,
brachytherapy and chemotherapy in the remaining stages.
In the last 15 years the main change improving local con-
trol and survival in patients with locally advanced tumours
is image-guided brachytherapy.1 This approach is based on
the use of 3D images, mainly magnetic resonance images
(MRI), for better delimiting tumour volumes and organs at
risk (OAR) as well as improving treatment planning.2,3 In addi-
tion, in parallel, applicators have been developed which allow
the combination of intracavitary and interstitial treatments,
improving tumour coverage and results related to disease
control in patients with poor tumour response and residual
parametrial disease.
The above clinical results were demonstrated by sev-
eral studies and later on the 2008 GEC-ESTRO initiated a
study on image guided intensity modulated external beam
radiochemotherapy and MRI-based adaptive brachytherapy in
locally advanced cervical cancer (EMBRACE study) with the
aim of collecting data from this multicentre experience with
the use of MRI-guided brachytherapy (MRI-GBT). This study
finished in December 2015. In 2012 the RetroEMBRACE study
was opened and was aimed at retrospectively collecting the
data of the patients treated in the hospitals participating in
the EMBRACE study before the initiation of this study. In 2017
the EMBRACEII study was opened, including patients with
advanced cervical cancer treated with intensity modulated
radiation therapy (IMRT), chemotherapy and MRI-GBT. The
aim of this article is to review the experience of the patients
from our hospital who were included in the above mentioned
studies.
2. Aim
To evaluate dosimetric and clinical findings of MRI-guided
HDR brachytherapy (HDR-B) for cervical carcinoma.
3. Material and methods
The Brachytherapy Unit of our hospital was opened in April
2008. Since then, all patients have been treated with MRI-GBT.
All cases with locally advanced cervical tumours are eval-
uated by the Committee of Gynaecological Tumours. Patients
undergo computerized tomography (CT), MRI and, in some
cases, positron emission tomography-CT (PET-CT) studies, and
pelvic-paraaortic lymphadenectomy is performed for staging.
External beam radiotherapy (EBRT) was initially 3D but
since 2011 IMRT is performed. All the cases received 45 Gy
over 5 weeks. In cases with lymph node remnants follow-
ing lymphadenectomy or findings of extracapsular extension
in some lymph nodes, a lymph node boost was carried out
after brachytherapy. Patients included in the EMBRACE II
study received an integrated boost at a dose of 55–57 Gy
according to the pelvic or paraaortic localization, respectively.
Before the availability of combined intracavitary-interstitial
applicators, patients with macroscopic residual parametrial
disease received a parametrial dose to achieve 60 Gy after
brachytherapy, taking into account the parametrial doses of
the brachytherapy.
Chemotherapy involved the use of cisplatin 40 mg/m2, 1
day/week during 5 weeks.
At week 5 of EBRT, all patients underwent MRI to evalu-
ate response and to choose the applicator for brachytherapy.
Brachytherapy was then done at weeks 6 and 7; first with 5
fractions of 6 Gy in 2 implants, and then with 4 fractions of
7 Gy after the entry in the EMBRACE study in 2011. In both
protocols MRI was performed after each implant for treatment
planning. The objective was to carry out all the treatment in
less than 55 days.
The GEC-ESTRO guidelines were followed for the delimi-
tation of volumes in MRI-GBT. The gross tumour volume b
(GTVb) was delimited with the residual tumour area visible
in T2 in MR. The high-risk clinical target volume (HR-CTV)
includes the GTVb, all the cervix, the residual area of micro-
scopic disease in parametrial tissue, and the vagina or uterine
cavity visible as grey areas in T2 in MR or palpable on clin-
ical examination. The intermediate risk CTV (IR-CTV) was
delimited taking into account the initial involvement, with
extension of 5–10 mm of the HR-CTV limited by the OAR. An
empty bladder, rectum from 2 cm under the vaginal applica-
tor to the peritoneal reflection and sigma from the reflection
to 1 cm above the uterine fundus were also delimited as OARs.
We also registered the doses at points A and B and the Inter-
national Commission of Radiation Units points at the bladder,
rectum and vagina and also at the vagina surface and at 0.5 cm
of depth.
Taking into account the dose of EBRT, the dosimetric objec-
tives were to achieve D90 HR-CTV > 100% of the prescription
dose, D90 IR-CTV > 60 Gy EQD2, D2cc rectum and sigma < 75 Gy
EQD2 and D2cc < 85 Gy EQD2.
The patients were followed every 3 months during the
first two years. The follow-up study always included physical
examination, cytology every 6 months, MR every 6 months and
CT annually. From years 3 to 5 the consultations were made
every 6 months, with MR every year. After year 5 the follow-ups
were carried out annually. The visits were alternated between
the Gynaecology Department and the Brachytherapy Unit.
General digestive, urinary and rectal toxicity were reported
according to the Common Terminology Criteria for Adverse
Events (CTCAE) v4 scale.
3.1. Statistical analysis
Treatment failures were classified according to the site of the
first tumoral relapse: local (cervix, uterus, vagina, parametria),
regional (pelvic or paraaortic nodes) or distant metastases.
Time intervals for local control, regional failure or overall sur-
vival were calculated from the date of biopsy to the date of
event or last follow-up appointment.
Toxicity was graded according to site and severity using the
National Cancer Institute CTCAE v4.03 (Common Terminology
Criteria for Adverse Events) guidelines. T de Student was used
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to compare median of doses between groups of toxicity grade
0–1 versus grade 2–3.
Kaplan–Meier test was used to calculate survival curves.




From November 2007 to July 2016 a total of 57 patients with a
mean age of 52 years (range: 27–85 years) were included in the
study.
Table 1 shows the characteristics of the patients included
in the study. Most had FIGO stage IIB (72.4%) and III (17.2%),
with 79.3% having squamous carcinoma and 20.7% adenocar-
cinoma. There was no case of small-cell carcinoma. Following
the radiological study with CT or PET, 29.8% showed lymph
node involvement. Lymphadenectomy was done in 53 patients
and showed 32 p with negative nodes, 19 p with iliac lymph
node involvement, 9 p with paraaortic involvement and 9 both.
Table 1 – Characteristics of the series.
N %
Age Median 51.2 27–85






Stage pN N0 32 56.1
N1 21 36.8
No lymphadenectomy 4 7
Histologic type Squamous 45 78.9
Adenocarcinoma 12 21.1
Grade Grade I 9 15.8
Grade II 29 59.9
Grade III 10 17.5
nr 9 15.8
Table 2 – Description of the treatment: external
radiotherapy (ERT) and RMI guide-brachytherapy (IGBT).
N %
Radiotherapy 3D 27 47.4
IMRT 30 52.6




Doses EQD2 GTV D100 103.7 53–345
CTV-HR D100 77.7 46–103
CTV-HR D90 94.4 50–131
D2cc bladder 83.5 55–103
D2cc rectum 69.1 54–92
D2cc sigmoid 64.7 48.7–81.7
The treatment administered is shown in Table 2. All the
women received a EBRT dose of 45 Gy in 25 fractions with 3D
in 27 patients and IMRT in 30 patients. A parametrial boost was
performed in 22% while 35% received a lymph node boost. A
total of 51 patients received concomitant chemotherapy with
cisplatin weekly for a median of 5 cycles.
MR-IGBT was carried out in 53 patients using high dose
rate brachytherapy. In 5 patients this was not performed; 2
were undergoing radiotherapy due to disease progression and
3 presented bad response to radiochemotherapy and required
rescue surgery. Interstitial brachytherapy was performed in
30.1% of the patients.
The mean HR-CTV in the first implant was 19.6 cc (5.2–79.6
cc), Median GTV 1.3 cc (0–14.3 cc): the mean D90 at HR-CTV was
94.5 Gy (50.8–131 Gy), D100 GTV was 115 Gy (59–138 Gy) D2cc to
the rectum was 69.1 Gy (54–92 Gy) bladder 83.5 Gy (55–103 Gy)
and sigma 66.7 Gy (48.73–81 Gy).
4.2. Local control
At a median follow up of 74.6 months (range: 16–122 m), a total
of 5 local recurrences were observed, leading to a 5-year local
control of 90.1% (Fig. 1). There were 2 patients with local pro-
gression and synchronous metastases during the radiotherapy
and 3 patients had only local failure, who underwent exenter-
ation and 1 is free of local disease.
On univariate analysis it was found that according to the
stage local control was achieved in 94.8% of patients in stages
Ib2-II and 70.1% in stages III-IVa (p = 0.032). According to his-
tological type, 94.9% had squamous carcinoma and 72.2%
adenocarcinoma (p = 0.01). With regard to lymph node involve-
ment following staging with lymphadenectomy, 100% of N0
patients achieved local control which was also obtained in
72.2% of N+ patients (p = 0.02).
There were no differences in local control between patients
who received a HR-CTV dose > 85 Gy (83% vs 84.4%) or CTV-HR
volume > 30 cc (92% vs. 93%). There were, however, differences
according to the implant used: 100% of the patients receiving
intracavitary brachytherapy achieved local control versus 66%
(p = 0.01) of those receiving interstitial brachytherapy.
4.3. Regional control and survival
Six patients developed lymph node recurrence, regional con-
trol at 5 years was 93.5%, being 92.1% in patients with stage
Ib2-II and 85.1% in stage III-IVa (p = 0.024). Regional control
according to disease staging after lymphadenectomy was
achieved in 100% of patients with N0, in 87% of patients with
positive paraaortic and negative iliac lymph nodes and in
71.4% of those with positive paraaortic and iliac lymph nodes
(p = 0.007) (Fig. 2).
Metastatic disease was developed by 9 patients with or
without regional or local disease. The metastasis-free survival
at 5 years was 84.1%
At the time of the analysis 13 patients had died due to
disease progression. The 5-year overall survival was 66.6%,
and the cancer specific overall survival was 74% (Fig. 2). Uni-
variate analysis showed the following results in relation to
patient survival: stage Ib2-II 83% vs. III-IVa 41% (p = 0.001); his-
tology: squamous carcinoma 78%, adenocarcinoma 59.7% (p:
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Fig. 1 – Local control and regional control.
ns); lymph node involvement following lymphadenectomy:
none 85% vs. paraaortic but not pelvic 72%, and paraaortic and
pelvic 35% (p = 0.010).
There were no differences in survival between the patients
who received 3D EBRT (66.3%) versus those receiving IMRT
(76.5%). On analysing patients who received a HR-CTV
dose > 85 Gy, the CEOS was 82.5% vs. 77%, and the volume of
CTV-HR < 30 cc: 81.8% and > 30 cc: 67%; but were not significant.
4.4. Toxicity
Acute grade 2–3 toxicity was 5.2% in the present study: rectal
15.7%, intestinal 15.7% and vesical 15.5%.
No patient presented grade 4 toxicity, but late grade 2–3
toxicity was observed: rectal 8.6%, intestinal 8.6%, and vesical
15.5%. The latter type of toxicity was due to an increase in
frequency in 6 cases; 2 for hydronephrosis and 1 vesicovaginal
fistula in 1 patient after rescue surgery for suspicion of tumour
persistence.
We analyzed late rectal and urinary morbidity in relation to
the dosimetric parameters. Patients presenting toxicity grade
0–1 vs. grade 2.3 have a mean D2cc of: rectal 67.7 Gy Vs 72.4 Gy
(p: ns) and bladder: 80.4 Gy vs. 83.2 Gy (p: ns): Patients with D2cc
to the rectum < 75 Gy showed rectal toxicity in 10%, including
14% with a dose > 75 Gy (p: ns Chi-square). Patients receiving
D2cc to the bladder < 85 Gy had a risk of grade 2–3 urinary tox-
icity of 13.7% versus 26.7% in patients with D2cc > 85 Gy (p: ns
Chi-square).
We also analyzed the appearance of late toxicity grade 2–3
according to the EBRT received with the following results: rec-
tal: 15% 3D vs. 10.5% IMRT (p: ns X2 Pearson), urinary: 22% 3D,
21% IMRT (p: ns).
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Fig. 2 – Cancer specific overall survival. Stages: Blue: Stage Ib-IIA1, Red: IIB, Brown: III-IVa.
5. Discussion
The objective of this study was to describe the experience
of a centre treating locally advanced cervical cancer. All the
patients underwent MRI-GBT. The treatment included previ-
ous 3D EBRT or IMRT when the treatment was performed after
2011. Weekly chemotherapy with cisplatin was administered
to 88% of the patients with the mean of 5 cycles. In addition, all
the patients also underwent radiological staging and surgical
lymph node staging by lymphadenectomy.
Since the initiation of the use of brachytherapy in our hos-
pital in 2008, we have used MRI-GBT. At that time we followed
the GEC-ESTRO guidelines which described how to delineate
the GTV, HR-CTV and IR-CTV tumour volumes in addition to
the OAR, including the bladder, rectum and sigma. We also
followed the recommendations on what dose should be given
to the OAR in order to obtain adequate local control with little
toxicity. These data were then based on the reports of individ-
ual hospitals. In 2007 Potter et al.4 published the results of a
series of 145 patients treated with MRI-GBT. Local control at 3
years was 88% with a cancer-specific survival of 68%. In their
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experience women achieving D90 HR-CTV > 87 Gy presented
local control of 95%. In addition, grade 3–4 toxicity was only
2%. In 2013 Lindegaard et al.5 described their results in 140
patients. Local control at 3 years was achieved in 91% with
a survival of 79%. In a study including 163 patients treated
with pulse dose rate brachytherapy carried out in 2013 Maze-
ron et al.6 achieved local control at 3 years of 92% and a survival
of 76%.
In 2008 recruitment for the EMBRACE study was begun, fin-
ishing in December 2015. Our group participated in the study
after 2011. In 2013 the centres which had participated in the
EMBRACE study were requested to retrospectively collect the
data of the patients treated with MRI-GBT prior to the entry in
the study. This was for the RetroEMBRACE study.
The results of our centre are similar to those published
by the previous institutions in addition to the data already
reported by EMBRACE.
In our study local control and cancer-specific survival were
90.6% and 72.4%, respectively, at 5 years, being 89% and
73%, respectively, in the RetroEMBRACE study including 731
patients.7 The data of local control in the EMBRACE study have
not been published yet, and only the preliminary results with a
short follow-up of 25 months were reported in the ESTRO 2017
meeting.8 Local recurrence was presented in 80 out of 1230
patients with a median time to recurrence of 11.5 months.
In our study patients with stages III-IVa and those with a
histology of adenocarcinoma had worse local control, being
95% in patients with stage Ib2-II and 72.9% in stages III-IVa
(p = 0.016). According to the histological type, local control was
achieved in 94.3% of squamous carcinomas and 79% of the
adenocarcinomas (p: ns). It is also important to note how stag-
ing with regional lymphadenectomy affected local control;
100% of patients with N0 achieved local control vs. 72.2% of
those who were N+ (p: 0.02).
We did not find any differences in local control in patients
receiving a HR-CTV dose > 85 Gy (84%) compared to those
receiving a lower dose (83%); nor did we find any differences
between patients with CTV-HR volume > 30 cc (92% vs. 93%).
Perhaps, this is in relation to the low number of local recur-
rences: 2 patients who did not complete the treatment and
only 3 patients who finished all the treatment. There were,
however, differences according to the implant used: patients
with intracavitary brachytherapy achieved local control of
100% vs. 66% of those receiving interstitial brachytherapy
(p = 0.01). The factors correlated with local control in the
RetroEMBRACE study7 were: HR-CTV (HR: 1.017 per cm3, p:
0.004), the dose evaluated with D90 (HR: 0.967 per Gy, P: 0.022)
and the total treatment time (HR: 1.023 per day, p: 0.004). A
dose < 85 Gy in the HR-CTV achieved local control in 94% of the
patients with a small HR-CTV (20 cc), 93% with an intermediate
CTV and 86% with large CTV (70 cc).
Regional control at 5 years was 93.5%: 92.1% in stages Ib2-
II and 85.1% in stage III-IVa (p: 0.024). We found that the
location of lymph node involvement by pelvic-paraaortic lym-
phadenectomy had an important prognostic value. Regional
control in N0 patients was 100%, including 87% in patients
with positive paraaortic but negative iliac lymph nodes and
71.4% in patients with positive paraaortic and iliac lymph
nodes (p:0.007) (Fig. 2). This is likely due to the use of a
lymph node boost in residual disease or with a high tumour
load defined by the lymphadenectomy. In the review by Smits
et al.9 in 2014 comparing the value of lymphadenectomy with
PET/CT, 4.15% of the patients with a negative study had pos-
itive adenopathies in the lymphadenectomy. Several studies
have described the value of lymph node boost in cervical can-
cer. In 2014 Vargo et al.10 described their results with RT with
IMRT extended to paraaortic nodes with a lymph node boost
in patients with positive adenopathies, reporting a regional
failure at 3 years in 5% and a survival of 73%, with a scarce
grade 3 toxicity of 4%.
The 5-year overall survival was 66.6%, and the specific cer-
vical carcinoma survival was 74%. In the univariate analysis
the prognostic factors were: stage Ib2-II: 83% vs. III-IVa: 41%
(p:0.001), histological type: squamous carcinoma: 78%, ade-
nocarcinoma: 59.7% (p: ns) and also lymph node involvement
after lymphadenectomy: N0: 85% vs. Paraaortic but not pelvic:
72%, paraaortic and pelvic: 35% (p = 0.010).
There were no differences between patients receiving 3D
EBRT and those receiving IMRT (66.3% vs. 76.5%, respectively).
On analysing the patients who received a HR-CTV dose > 85 Gy,
the differences in survival were 85.7% vs. 74%, but these values
were not significant.
With regard to toxicity, acute grade 2–3 toxicity in our study
was rectal in 5.2%, intestinal in 15.7% and vesical in 15.5%.
Late grade 2–3 toxicity was presented as rectal in 6%, intesti-
nal in 8.6% and vesical in 15.5%, with no grade 4 toxicity being
observed. In our study the use of IMRT reduced rectal toxic-
ity from 15% with 3D EBRT to 10.5% with IMRT. Rectal toxicity
was greater with D2cc > 75 Gy and vesical toxicity was greater
with D2cc > 85 Gy, although the differences were not signifi-
cant, likely due to the size of the study population.
The results of the RetroEMBRACE study showed late grade
3–5 morbidity11: 5% vesical and 7% gastrointestinal, being sim-
ilar to the results in our centre. In the EMBRACE I study grade
2–3 urinary toxicity with incontinence was 16.4%, 16.2% in
changes in urinary frequency and 11% with cystitis.12 Ureteral
stenosis was observed at 5 years in 3.4%. With regard to rec-
tal toxicity,13 7.7% of the patients presented grade 2–4 toxicity.
On analysis of the correlation of toxicity with parameters of
dosimetry, the patients with D2cc < 65 Gy had a two-fold lower
risk of presenting proctitis, and patients with D2cc > 75 Gy had
a 12.5% risk of presenting fistula at 3 years versus 0–2.7% in
patients receiving lower doses. None of the patients in our
study presented rectal fistula. The correlation between dose
and volume has been demonstrated in other studies.14 In a
series of the Hospital La Fe, they had similar results in toxi-
city: with a median follow-up of 19 months (3–35 m). Urinary
and gastrointestinal G ≥ 3 toxicities occurred in 4.8% and 2.4%
patients, respectively. These data show that IGBT is sure, also
with interstitial treatments.15
6. Conclusion
In the present study the results obtained with the use of MRI-
GBT in all the women with cervical cancer are comparable to
those of the most important multicentre studies reported to
date, with scarce, albeit manageable, late toxicity.
The future is leading in the direction of the EMBRACE
II study which is aimed at reducing toxicity in women
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showing good response after radiochemotherapy and inten-
sifying brachytherapy treatment, especially with interstitial
brachytherapy, in order to improve local control and survival
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